Emerging Treatment Options in Relapsed Refractory Multiple Myeloma

A panel of experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide practical considerations for regimen selection and emerging treatment options.
EP 1: R/R Multiple Myeloma Rationale for Decreased Response

December 30th 2020

Key opinion leaders discuss why patients with multiple myeloma experience increasingly decreased response to therapy over time.

EP 2: Importance of MRD Negativity in Changing Relapse Patterns

January 6th 2021

A discussion on the importance of MRD (minimum residual disease) negativity in changing relapse patterns for patients with multiple myeloma.

EP 3: Treating Biochemical Relapses in Multiple Myeloma

January 6th 2021

Expert physicians provide insight into their strategy for treating biochemical relapse in patients with multiple myeloma.

EP 4: Upfront Daratumumab Impact on Relapse Treatment

January 13th 2021

Key opinion leaders consider how the approval of daratumumab in the upfront setting for patients with relapsed multiple myeloma has impacted treatment strategies.

EP 5: CANDOR Trial Overview and Regimen Complications

January 13th 2021

An overview of the data from the CANDOR trial presented at the ASH (American Society of Hematology) 2020 annual meeting and discussion on how to manage various complications from the trial regimen.

EP 6: Clinical Significance of DKd Dosing Flexibility

January 20th 2021

Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial.

EP 7: Therapy Selection for Newly Diagnosed Multiple Myeloma

January 20th 2021

Experts in the management of multiple myeloma discuss treatment selection for newly diagnosed patients, with consideration of the ENDURANCE trial and its shortcomings.

EP 8: ASH 2020 Data: DKd Versus DVd Implications

January 27th 2021

A discussion on the practical implication of the data from the ASH (American Society of Hematology) 2020 Annual Meeting regarding DKd versus DVd.

EP 9: Impact of the Phase 3 APOLLO Trial Recent Findings

January 27th 2021

Key opinion leaders provide an overview of the recent findings from the APOLLO phase 3 study, and consider whether the findings have impacted their treatment algorithm in regards to potential for earlier response.

EP 10: Implications of the IKEMA Interim Analysis

February 3rd 2021

Expert physicians consider the practical implications of the IKEMA interim analysis of isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

EP 11: The Role of Venetoclax in R/R Multiple Myeloma

February 3rd 2021

Key opinion leaders consider the role of venetoclax in managing patients with relapsed/refractory multiple myeloma.

EP 12: The Future of R/R Multiple Myeloma Management

February 10th 2021

Experts in the management of multiple myeloma consider promising developments for the future of relapsed/refractory treatment, with special consideration to bispecific antibodies and CAR (chimeric antigen receptor) T-cell therapy.